Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Can arginase inhibitors be the answer to therapeutic challenges in Alzheimer's disease?
Neurotherapeutics 15, 1032-1035 (2018)
Verlagsversion Forschungsdaten DOI
While the extensive hunt for therapeutics combating Alzheimer's disease (AD) has fallen short of delivering effective treatments, breakthroughs towards understanding the disease mechanisms and identifying areas for future research have nevertheless been enabled. The majority of clinical trials with beta- and gamma-secretase modulators have been suspended from additional studies or terminated due to toxicity issues and health concerns. The lack of progress in developing innovative AD therapies has also prompted a resurgence of interest in more traditional symptomatic treatments with cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, as well as in the research of immune response modulators. Recently, evidence has emerged showing that inhibitors of arginine metabolism and in particular blockers of arginase, an enzyme that catalyzes the breakdown of L-arginine, could present an effective therapeutic candidate for halting the progression of AD and boosting cognition and memory. In this commentary, we present a brief overview of reports on arginase inhibitors in AD mouse models and discuss emerging advantages and areas for careful consideration on the road to clinical translation.
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Schlagwörter L-norvaline ; Arginine Metabolism ; Nitric Oxide ; Amyloid Beta ; Cognitive Enhancers ; Alzheimer's Disease; Triple-transgenic Model; Amyloid-beta; Secretase Inhibitors; Arginine Metabolism; Difluoromethylornithine; Oligomers; Lessons; Enzyme; Muscle; Trial
ISSN (print) / ISBN 1933-7213
Quellenangaben Band: 15, Heft: 4, Seiten: 1032-1035
Verlagsort New York, NY
Begutachtungsstatus Peer reviewed